Bevacizumab plus chemotherapy for ovarian cancer

被引：0
|
作者：
Ozkan, Judy
机构：
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 06期
关键词：
D O I：
10.1016/S1470-2045(14)70142-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E202 / E202
页数：1
相关论文
共 50 条
  • [41] Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer
    Choi, Hyun-Jin
    Lee, Yoo-Young
    Choi, Chel Hun
    Kim, Tae-Joong
    Lee, Jeong-Won
    Bae, Ji Hye
    Bae, Duk-Soo
    Kim, Byoung-Gie
    CURRENT PROBLEMS IN CANCER, 2020, 44 (05)
  • [42] Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer A retrospective study
    Gao, Jie
    Li, Fang
    Liu, Zihao
    Huang, Mengli
    Chen, Huoming
    Liao, Guoqing
    Meng, Jichang
    Wang, Qing
    Zhao, Hui
    Li, Chenxi
    Ji, Jing
    Cai, Shangli
    Du, Nan
    MEDICINE, 2021, 100 (35)
  • [43] Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer
    Reck, Martin
    Wehler, Thomas
    Orlandi, Francisco
    Nogami, Naoyuki
    Barone, Carlo
    Moro-Sibilot, Denis
    Shtivelband, Mikhail
    Gonzalez Larriba, Jose Luis
    Rothenstein, Jeffrey
    Fruh, Martin
    Yu, Wei
    Deng, Yu
    Coleman, Shelley
    Shankar, Geetha
    Patel, Hina
    Kelsch, Claudia
    Lee, Anthony
    Piault, Elisabeth
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (22) : 2530 - +
  • [44] Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
    Shui, Lin
    Wu, Yu-Shen
    Lin, Huapeng
    Shui, Pixian
    Sun, Qin
    Chen, Xiaopin
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 48 (05) : 1870 - 1881
  • [45] Bevacizumab plus chemotherapy versus combination chemotherapy only in metastatic, recurrent, and persistent cervical cancer
    Choi, H.
    Kim, B. G.
    Lee, Y. Y.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 275 - 275
  • [46] Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer
    Husain, Amreen
    Wang, Yan
    Hanker, Lars C.
    Ojeda, Belen
    Anttila, Maarit
    Breda, Enrico
    Vuylsteke, Peter
    Pujade-Lauraine, Eric
    GYNECOLOGIC ONCOLOGY, 2016, 142 (03) : 465 - 470
  • [47] Olaparib plus bevacizumab improves progression-free survival in ovarian cancer
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2020, 21 (02): : E71 - E71
  • [48] Ifosfamide plus cisplatin as primary chemotherapy of advanced ovarian cancer
    Vallejos, C
    Solidoro, A
    Gomez, H
    Castellano, C
    Barriga, O
    Galdos, R
    Casanova, L
    Otero, J
    Rodriguez, W
    GYNECOLOGIC ONCOLOGY, 1997, 67 (02) : 168 - 171
  • [49] Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer
    Wei Wang
    Li-Rong Zhao
    Xiu-Qiang Lin
    Fen Feng
    World Journal of Gastroenterology, 2014, (21) : 6691 - 6697
  • [50] Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer
    Wang, Wei
    Zhao, Li-Rong
    Lin, Xiu-Qiang
    Feng, Fen
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (21) : 6691 - 6697
12345